MaxCyte and TG Therapeutics work together to advance the development of azer-cel, an allogeneic CD19 CAR T therapy, through the use of cutting-edge cell engineering technology.

In order to use its Flow Electroporation® technology and ExPERT™ platform to develop and market azer-cel, an experimental allogeneic CD19 CAR T cell treatment for autoimmune disorders, TG Therapeutics and MaxCyte, Inc. have signed a strategic platform licensing (SPL) agreement.

MaxCyte receives yearly license payments and program-related income under this arrangement, while TG Therapeutics acquires non-exclusive rights to MaxCyte's cutting-edge cell engineering technology.

Precision BioSciences was the original developer of Azer-cel, which TG Therapeutics purchased in January 2024 for use in non-oncology indications, including autoimmune illnesses. In 2025, TG Therapeutics plans to begin a Phase 1 study for progressive multiple sclerosis (MS) when the FDA approves its IND application.

The next-generation electroporation technology offered by MaxCyte's ExPERT™ instrument range guarantees excellent transfection efficiency, scalability, and improved functionality—all essential for the advancement of allogeneic T cell immunotherapies. Through this partnership, Azer-Cel's development and production will be streamlined, potentially increasing its use in treating a range of autoimmune conditions.

In order to propel innovation in the treatment of autoimmune diseases and next-generation biologics, TG Therapeutics and MaxCyte have partnered to bring innovative cell-based therapies to market.